INmune Bio, Inc. Q4 FY2025 earnings call

David Moss began by outlining the company's progress and strategic priorities. Mark Lodell updated on the Cordstrom platform, highlighting progress in RDEB with clinical data, preparation for regulatory submissions, and the platform's broader potential. C.J. Barnum provided an update on XPRO's Alzheimer's disease development, including alignment with the FDA and phase III preparation. Corey Elsperman reviewed financial results such as net loss, R&D and G&A expenses, and cash position. David Moss also emphasized the company's focus on executing regulatory, clinical, and strategic milestones across the portfolio.

Not explicitly detailed with absolute financial figures and revenue contribution percentages for each product segment in the transcript

Plan to file the MAA in the UK by the end of summer 2026; preparing for phase III of XPRO with an adaptive trial design; advancing partnership and funding discussions for XPRO's late-stage development; focus on capital efficiency and hitting data-driven milestones to maximize shareholder value

Forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those projected. Need to refer to the company's SEC filings for detailed risk factors as these forward-looking statements speak only as of their made date and may change due to various circumstances

Q: What are anticipated differences between an MAA and an FDA submission?

A: Sensitivity about using UK donor materials in the US; need to create new master seed stock from US-tested donors but will present the same data set to the FDA as to the MHRA.

Q: Any interest/interactions with potential partners at ADPD?

A: Ongoing discussions with groups; intend to find business development help as the program is attractive for mid-sized to large pharma due to its potential in a large market and logical trial design linkage